Britta Væver Bysted

Pharmacokinetic and Pharmacodynamic Characteristics of Dasiglucagon, a Novel Soluble and Stable Glucagon Analog

Ulrike Hövelmann, Britta Væver Bysted, Ulrik Mouritzen et al. · Diabetes Care · 2017 · 108 citations

A randomized, double‐blind trial demonstrating bioequivalence of the current recombinant activated factor VII formulation and a new robust 25°C stable formulation

Britta Væver Bysted, B. SCHARLING, Tom Møller et al. · Haemophilia · 2007 · 41 citations

Pegylated Long-Acting Human Growth Hormone Is Well-Tolerated in Healthy Subjects and Possesses a Potential Once-Weekly Pharmacokinetic and Pharmacodynamic Treatment Profile

Michael Højby Rasmussen, Britta Væver Bysted, Thomas W. Anderson et al. · The Journal of Clinical Endocrinology & Metabolism · 2010 · 40 citations · Full text

Embryonic developmental stages in relation to the LH peak in dogs.

Britta Væver Bysted, S.J. Dieleman, P. Hyttel et al. · PubMed · 2001 · 27 citations

Oocyte, Fertility, Plasma Progesterone +22

Prolonged half-life of glycoPEGylated rFVIIa variants compared to native rFVIIa

Ditte M. Karpf, Brit B. Sørensen, Mette B. Hermit et al. · Thrombosis Research · 2011 · 20 citations

Biology, Prolonged Half-life